#32026B01518Statement of revenue and expenditure for the 2026 financial year – European Union Drugs Agency (EUDA)
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This document outlines the projected revenues and expenditures for the European Union Drugs Agency (EUDA) for the financial year 2026. It provides detailed estimates of subsidy income from the European Union as well as other funding sources, alongside their respective expenditures aimed at facilitating the operational and administrative functions of the agency.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Introduction of new subsidy categories
- Adjustments in projected staff expenditure
- Increase in total revenue estimates
Obligations
What this law requires
EUDA must execute expenditures totaling €38,444,080 for the 2026 financial year, allocated as follows: €19,803,292 for staff costs, €4,958,642 for administrative support, €12,449,056 for operational activities, and €1,233,090 for special projects
EUDA must maintain staff establishment with a maximum of 101 total posts in 2026 (4 permanent AD posts, 97 temporary posts across AD and AST grades), as specified in the establishment plan
EUDA must allocate €19,803,292 in non-differentiated appropriations for staff in active employment in 2026, matching both commitment and payment amounts
EUDA must utilize €12,449,056 in differentiated appropriations for project-related operational activities in 2026, with equal commitment and payment authorization
EUDA must employ a maximum of 41 contract staff and seconded national experts (expressed in full-time equivalents) in 2026, comprising 40 contract staff across four functional grades and 1 seconded national expert